LXE408 is an oral antileishmanarial compound that selectively targets the kinetoplastid proteosome vs. the mammalian proteosome. The prior candidate, GNF6702, had solubility-limited oral absorption, which could have been addressed with a specialized formulation but would have increased the cost and limited use in developing countries. A [...]
< 1 minute read
Sep. 18, 2021
LXE408: A Kinetoplastid-Selective Proteasome Inhibitor
LXE408
kinetoplastid-selective proteasome inhibitor oral antileishmanial in Ph. I in HV From 3M cmpd antiprolif. screen + opt. J. Med. Chem., Jul. 29, 2020 Novartis (GNF), San Diego, CA